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1. The clinical utility of plasma metadrenalines for 
examination of sympatho-adrenal function and cate­
cholamine metabolism was assessed from plasma 
measurements of these metabolites in a number of 
clinical conditions (hypertension, cardiac failure, bila­
teral adrenalectomy and X-chromosomal deletions of 
the gene for monoamine oxidase), and before and 
during activation of sympathetic outflow or infusions 
of noradrenaline and adrenaline.
2. Plasma concentrations of normetadrenaline were 
less than 25% of those of noradrenaline, concenti, 
rations of metadrenaline and adrenaline were similar 
and those of sulphate-conjugated metadrenalines were 
20- to 30-fold higher than free metadrenalines. 
Hypertensive patients had elevated plasma concent­
rations of adrenaline, noradrenaline and conjugated 
but not free metadrenalines. Cardiac failure patients 
had 2- to 4-fold increases in plasma noradrenaline 
and free and conjugated normetadrenaline. Adrenalec­
tomy resulted in undetectable plasma concentrations 
of adrenaline, 91-97% decreases in free and conju­
gated metadrenaline and a 40% decrease in normet­
adrenaline relative to noradrenaline. Patients with X- 
chromosomal deletions of the gene for monoamine 
oxidase had 6- and 16-fold increases in plasma free 
and conjugated normetadrenaline and 2- and 4-fold 
increases in free and conjugated metadrenaline.
3. Infusion of catecholamines increased plasma con­
centrations of free metadrenalines by less than 6% of 
increases in precursor amines, indicating that most 
plasma normetadrenaline (84%) and metadrenaline
(90%) is derived from metabolism of catecholamines
before their entry into the circulation. Considerable 
O-methylation of catecholamines within the adrenals 
explains why sympatho-adrenal activation resulted in 
smaller proportional increases in plasma metadrena­
lines than catecholamines.
4. Plasma metadrenalines provide supplementary 
information about sympatho-adrenal activity to that 
provided by catecholamines, but are more useful for 
examination of the extraneuronal inactivation of 
catecholamines, particularly detection of neurochemi­
cal phenotypes in genetic disorders of catecholamine 
metabolism. Significant formation of metadrenalines 
within chromaffin tissue explains why measurements 
of plasma metadrenalines provide an extraordinarily 
sensitive method for diagnosis of phaeochromo- 
cytoma.
INTRODUCTION
The metadrenalines, normetadrenaline and metad­
renaline, are produced by O-methylation of norad­
renaline and adrenaline, a reaction catalysed by 
catechol-O-methyltransferase (COMT) [1]. Because 
COMT is localized mainly in non-neuronal tissues, 
normetadrenaline is produced by extraneuronal 
metabolism of the noradrenaline released by nerves 
that escapes reuptake [2]. In contrast, the deami- 
nated metabolites of noradrenaline, dihydroxyphe- 
nylglycol (DHPG) and methoxyhydroxyphenylgly-
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col, are derived largely from the intraneuronal meta­
bolism of the noradrenaline that leaks from storage 
vesicles [3, 4]. The above metabolic differences 
suggest that normetadrenaline, in conjunction with 
other metabolites, may offer a useful marker of 
noradrenaline release as distinct from noradrenaline 
turnover [5]. In rats, measurements of plasma 
metadrenalines have indeed been shown to offer a
useful method for examination of extraneuronal
b
uptake and metabolism of catecholamines [6-8]. 
Studies of plasma metadrenalines in humans, how­
ever, are limited [9-11].
The clinical utility of plasma metadrenalines for 
examination of sympatho-adrenal function and cate­
cholamine metabolism was therefore explored by 
studies that answered the following questions. Do 
the metadrenalines provide useful markers of 
sympatho-adrenal activity at rest and during sym­
pathetic activation associated with mental stress, 
lower body negative pressure and cycling exercise? 
What proportions of plasma normetadrenaline and 
metadrenaline derive from metabolism of circulating 
catecholamines? Can plasma metadrenalines provide 
additional information to plasma catecholamines in 
clinical conditions affecting sympatho-adrenal func­
tion such as adrenalectomy, heart failure, hyperten­
sion, angina pectoris, renal artery stenosis and X- 
chromosomal delations or mutations affecting 
monoamine oxidase (MAO)?
METHODS 
Subjects
The study included 81 normal control subjects, 50 
patients with essential hypertension, 24 patients with 
angina, 35 patients with heart failure, 11 patients 
with renal artery stenosis, 11 patients with bilateral 
adrenalectomies, five Norrie disease patients with X- 
chromosomal deletions affecting MAO and one 
patient who underwent inferior vena cava regional 
blood sampling to localize the site of a suspected 
phaeochromocytoma. Subjects were studied as part 
of ongoing protocols at three different institutions: 
the National Institutes of Health, the University of 
Göteborg and St Radboud University Hospital. All 
procedures were approved by the appropriate ethics 
committee and all patients (and parents of Norrie 
disease patients) gave informed consent before blood 
samples were taken or studies began. Blood samples 
were taken with subjects in the supine position. The 
physical characteristics (age and sex) and sites of 
blood sampling for the subjects of the various 
groups are summarized in Table 1.
Hypertension. A diagnosis of essential hyperten­
sion was made if the mean of blood pressure values 
determined on three separate outpatient visits was 
higher than 140 mmHg (systolic) or 90 mmHg (dias­
tolic). At each visit, blood pressure was measured as 
the mean of two readings after at least 5 min of 
supine rest. Secondary hypertension was excluded
Table I. Physical characteristics of subjects (age and gender) and 
site of blood sampling
Mean age
[years (range)]
Gender
(M/F)
Sampling site 
(arterial/venous)
Control subjects (n =  8l) 38 (20-72) 47/34 15/71*
Essential hypertension
(n =  50) 42(19-46) 26/24 0/50
Angina pectoris (n =  24) 57 (37-71 ) 18/6 24/0
Cardiac failure (n =  35) 55 (34-75) 30/5 31/4
Renal artery stenosis
(n —13) 51 (25-69) 7/6 8/5
Adrenalectomy (n — 11 ) 47 (32-66) 2/9 0/11
Norrie disease (/? =  5) 16(12-23) 5/0 0/5
includes five subjects from whom samples were taken from both 
arterial and venous sites.
according to standard clinical criteria. Hypertensive 
patients remained unmedicated for 2 weeks before 
blood samples were taken.
Angina pectoris. Patients with angina pectoris 
included 11 patients with chest pain and coronary 
artery disease (angiographic narrowing of more than 
50% of the lumen of any major epicardial vessel) 
and ten patients with chest pain but normal coron­
ary angiograms. Patients were studied after disconti­
nuation of medication (/2-adrenoceptor blockers, 
calcium-channel antagonists, nitrates) at admission.
Renal artery stenosis. Renal artery stenosis was 
diagnosed on the basis of a stenosis greater than 
50% as determined by digital subtraction arteriogra­
phy of the renal arteries. Two patients had renal 
failure.
Cardiac failure. Cardiac failure was secondary to 
coronary artery disease or idiopathic dilated cardio­
myopathy. Blood samples were taken 12 h after 
patients received their last medication, typically a 
combination of digoxin, calcium-channel blockers, 
angiotensin-converting enzyme inhibitors, nitrates or 
diuretics.
Adrenalectomy. Subjects with bilateral adrenalec­
tomies included ten patients who had both adrenals 
removed for treatment of Cushing’s syndrome 
(primary pigmented nodular adrenal disease, n =  5; 
ectopic Cushing’s syndrome, n =  2; pituitary 
Cushing’s disease, n ~  3) and one patient who under­
went the procedure during removal of phaeochro- 
mocytomas on both adrenals. Venous blood sam­
ples were collected from patients in the morning, 
immediately before their normal steroid replacement 
dose.
Norrie disease. Patients with X-chromosomal 
deletion-related Norrie disease affecting the genes 
for both MAO-A and MAO-B [12, 13] included
five subjects from three different families described 
elsewhere [13-16].
Inferior vena cava blood sampling. One patient 
underwent inferior vena cava sampling of blood to 
localize a suspected phaeochromocytoma. The 
patient was subsequently determined not to harbour 
a phaeochromocytoma, but samples from the infer-
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ior vena cava and renal and adrenal veins were 
analysed to assess the possible contribution of the 
adrenal medullae to circulating plasma concent­
rations of metadrenalines.
Activation of sympathetic outflow
i
Lower body negative pressure. In five control 
subjects and five hypertensive patients, blood 
samples were taken simultaneously from a brachial 
artery and from a deep antecubital vein, before and 
15 min after the start of lower body negative pres­
sure (at —40 mmHg).
Mental challenge. In 11 patients with microvascu- 
lar angina, arterial blood samples were taken in the 
supine position before and 5 min after subjects 
started playing a video game, previously demon­
strated to elicit increases in plasma catecholamines
[17].
Exercise. Twenty-eight patients, including 18 
patients with cardiac failure and ten control sub­
jects, performed cycling exercise in the supine 
position. Arterial blood samples were taken before 
and during the last minute of cycling exercise, 
between 10 and 24 min after the start of exercise.
Infusions of 3H-labelled catecholamines
All patients who underwent the manipulations 
described above received infusions of 
[3H]noradrenaline (L-2,5,6-[3H]noradrenaline, 40- 
60Ci/mmol; New England Nuclear, Boston, MA, 
U.S.A.) either delivered alone or in combination 
with [ 3H]adrenaline (L-iV-methyl-[3H] adrenaline, > 
65-75 Ci/mmol; New England Nuclear). The radio­
tracers were infused into a forearm vein at 1.0-
1.5/iCi/min. Blood samples were taken at intervals 
between 15 and 145 min after the start of infusions. 
The preparation, storage and handling of the radio­
tracers has been described in detail elsewhere [18].
Analytical methods
Metadrenaline assays. The metadrenalines (normet­
adrenaline and metadrenaline) were extracted from 
2 ml samples of plasma using solid-phase ion- 
exchange columns and were quantified by liquid 
chromatography with electrochemical detection 
[11]. Samples from subjects who received intrave­
nous infusions of 3H-labelled catecholamines under­
went timed collections of the eluant leaving the 
electrochemical cell, enabling determination of 
plasma concentrations of 3H-labelled normetadrena­
line and metadrenaline by liquid-scintillation spec­
troscopy. Plasma concentrations of sulphate- 
conjugated normetadrenaline and metadrenaline 
were determined from 0.25 ml samples of plasma 
that were subjected to enzymic deconjugation by 
incubation with 0.2 unit of sulphatase (Sigma; St 
Louis, MO, U.S.A.) for 30min at 37°C. Inter-assay 
coefficients of variation were 12.2% for normetadren­
aline and 11.2% for metadrenaline. Intra-assay co­
efficients of variation were 4.2% for normetadren­
aline and 3.3% for metadrenaline.
Catechol assays. The catechols (noradrenaline, 
adrenaline and DHPG) were determined by liquid 
chromatography with electrochemical detection after 
extraction by alumina adsorption [19]. Inter-assay 
coefficients of variation were 6.5% for noradrenaline,
11.4% for adrenaline and 8.4% for DHPG. Intra­
assay coefficients of variation were 1.9% for norad­
renaline, 3.0% for adrenaline and 4.8% for DHPG.
Data analysis
Calculations. The proportion (P ) of endogenous 
free normetadrenaline in plasma formed from meta­
bolism of circulating noradrenaline, or of free 
metadrenaline formed from circulating adrenaline 
(i.e. that derived from the catecholamine after its 
release or entry into the plasma compartment) was 
estimated according to a previously established 
method [6], using the equation:
P = ( [3H]M /[3H]C)/(M/C)
where C is the plasma concentration of endogenous 
catecholamine precursor (pmol/ml), M  is the plasma 
concentration of endogenous metabolite (pmol/ml), 
[3H]C is the steady-state plasma concentration of 
intravenously infused 3H-labelled catecholamine 
(d.p.m./ml) and [3H]M is the respective plasma 
concentration of the 3H-labelled metabolite (d.p.m./ 
ml) during infusion of 3H-labelled catecholamine 
precursor.
Statistical methods. Results are expressed as 
means+ SEM. Plasma concentrations of normetad­
renaline and metadrenaline were not normally dis­
tributed. Therefore, for the most part, levels of 
statistical significance were determined using non- 
parametric methods: Wilcoxon’s signed-rank sum 
test was used for comparisons of paired data, the 
Mann-Whitney U -test was used for comparisons of 
non-paired data, and the significance of relation­
ships was assessed using Spearman’s rank correla­
tion coefficient. Where parametric methods were 
used (i.e. analysis of variance to assess gender-group 
interactions), levels of significance were determined 
after logarithmic transformation of the data. Unless 
stated, statistical significance was defined as
P<0.05.
RESULTS 
Free and conjugated metadrenalines
Forearm venous plasma concentrations of nor­
metadrenaline in control subjects were low, averag­
ing less than 25% of those of noradrenaline and 
ranging between 0.09 and 0.62 pmol/ml (Table 2). In 
contrast, venous plasma concentrations of met­
adrenaline were similar to those of adrenaline, rang­
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Table 2. Forearm venous plasma concentrations of catecholamines and free and total metadrenalines in control 
subjects, essential hypertensive patients, patients with bilateral adrenalectomy and patients with Norrie disease, Values 
are expressed as means ±SEM. ^Significantly higher concentrations (P<0.05) compared with control subjects. fSignificantly lower 
concentrations (P <  0.05) compared with control subjects. Differences were determined by the Mann-Whitney U-test,
Control subjects
(" =  71)
Hypertension
(n =  50)
Adrenalectomy
(n= l l )
Norrie disease 
(n =  5)
Normetadrenaline (pmol/ml) 0.29 ± 0.02 0.31+0.02 0.21 ±0.03 1.77 ± 0.1 *
Normetadrenaline sulphate (pmol/ml) 7.68 ± 0.49 8.96 ±0.46* 8.67 ± 0.53 120.70 +  28.46*
Noradrenaline (pmol/ml) 1.28 ± 0.08 1.48 ±0.09* 1.94 ± 0.38 2.76 ± 0.3*
Metadrenaline (pmol/ml) 0.14 +  0.01 0.15 ± 0.01 0.012 ± 0.0031 0.37 ±0.15*
Metadrenaline sulphate (pmol/ml) 3.13 +  0.14 3.90 ±0.27* 0.081 ±0.0 I f 12.67 ± 1.75*
Adrenaline (pmol/ml) 0.11 ±0.01 0.18 ±0.02* <  0.02t 0.15 ± 0.05
DHPG (pmol/ml) 5.59 +  0.23 5.58 ±0.26 4.87 +  0.65 <  0.02t
ing between 0.03 and 0.36 pmol/ml. Both normet­
adrenaline and metadrenaline were extensively 
sulphate-conjugated, so that concentrations of the 
conjugates were 20- to 30-fold higher than concent­
rations of free compounds.
(r = 0.30, P c  0.002), but no age-related relationships 
were apparent for adrenaline or metadrenaline. The 
observed gender differences in plasma catechola­
mines and metadrenalines were unrelated to any 
gender difference in age distribution (39 ±  1 years in 
males compared with 41 ± 2  years in females).
Forearm arteriovenous differences
In the ten subjects from whom simultaneous 
arterial and forearm venous blood samples were 
obtained, arteriovenous differences in plasma con­
centrations of metadrenalines showed a similar, 
albeit less dramatic, pattern to the parent amines. 
Venous concentrations of metadrenaline were 
24 + 9% lower ( P <  0.05) than arterial concent­
rations, whereas venous concentrations of normet­
adrenaline were slightly (18 + 14%), but not signifi­
cantly, higher than »arterial concentrations. Forearm 
venous concentrations of adrenaline were 75 + 2% 
lower (PcO.Ol) than arterial concentrations, whereas 
venous noradrenaline concentrations were 23 + 7% 
higher (P c  0.05) than arterial concentrations.
Influence of gender and age
Gender. Consistent sex differences in forearm 
venous plasma concentrations of metadrenaline, 
metadrenaline sulphate and adrenaline were
observed for both hypertensive and control subjects. 
Plasma adrenaline was higher ( P <  0.001) in males 
than in females (0.17 + 0.02 compared with 
0.11+0.01 pmol/ml), a difference that was significant 
for both hypertensive and normotensive groups 
considered alone. This difference was also reflected 
in higher ( P c  0.02) concentrations in males than 
females of both metadrenaline (0.16 + 0.01 compared 
with 0.13 + 0.01 pmol/ml) and metadrenaline sul­
phate (4.00 +  0.23 compared with 3.18 + 0.17 pmol/ 
ml). Except for higher (P c  0.05) concentrations of 
normetadrenaline in female compared with male
control subjects (0.32 + 0.02 and 0.26 ±0.02 pmol/ml,
respectively), there were no other gender differences 
in noradrenaline and its O-methylated metabolites.
Age. There were weak positive relationships 
between age and plasma concentrations of noradre­
naline (r=0.29, P <  0.002), normetadrenaline 
(r = 0.21, P c  0.05) and normetadrenaline sulphate
Comparisons among subject groups
Due to the differences between arterial and fore­
arm venous plasma concentrations of metadrena­
lines and catecholamines, comparisons among sub­
ject groups were made according to the site of 
blood sampling.
Hypertension. In patients with essential hyperten­
sion, venous plasma concentrations of noradrenaline 
and adrenaline and of conjugated normetadrenaline 
and metadrenaline were 15-25% higher ( P c  0.02) 
than in control subjects, whereas concentrations of 
unconjugated normetadrenaline and metadrenaline 
were not significantly different (Table 2). Increased 
plasma concentrations of metadrenaline sulphate 
and adrenaline in hypertensive patients were inde­
pendent of gender. In contrast, there was a signifi­
cant (PcO.Ol) group-gender interaction for plasma 
normetadrenaline, such that plasma concentrations 
of this metabolite were higher in hypertensive than 
normotensive males (0.35 +  0.03 compared with 
0.26 ±0.02 pmol/ml), but not in females (0.28 +  0.03 
compared with 0.32 ±0.02 pmol/ml). There was no 
associated group-gender interaction for plasma 
noradrenaline.
Bilateral adrenalectomy. In adrenalectomized sub­
jects, forearm venous plasma concentrations of adre­
naline were below the detection limits of the assay 
(<0.015 pmol/ml). Plasma concentrations of free 
and conjugated metadrenaline were detectable, but 
were decreased (P <  0.001) by more than 91% com­
pared with control subjects (Table 2). Adrenalec­
tomy was associated with decreased plasma concen­
trations of normetadrenaline and increased concen­
trations of noradrenaline, but these differences did 
not reach significance. Considered together, how­
ever, the ratio of plasma normetadrenaline to nor­
adrenaline concentrations was 43% lower (PcO.Ol) 
in adrenalectomized subjects than in control sub­
jects (0.144 + 0.013 compared with 0.254±0.015).
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Table 3. Arterial plasma concentrations of catecholamines and free and total metadrenalines in control subjects and 
patients with angina pectoris, renal artery stenosis and cardiac failure* Values are expressed as means ±SEM. ^Significantly 
higher concentrations (P<0.05) compared with control subjects, as determined by Mann-Whitney U-test. tSamples from these 
groups include some taken from venous sampling sites (see Table I), but observed differences remained significant when comparisons 
were made with the control subjects from whom venous samples were taken (see Table 2).
Control subjects
(n =  !5)
Angina
(„ =  24)
Renal artery
stenosisf 
(n =  !3)
Cardiac failuref 
(n =  35)
Normetadrenaline (pmol/ml) 0.20 ± 0.01 0.25 +  0.02 0.48 ±0.12* 0.46 ± 0,07*
Normetadrenaline sulphate (pmol/ml) 6.78 ± 0.49 10.80 ± 1.25* 14.40 ±2.28* 24.25 ± 4.98*
Noradrenaline (pmol/ml) 1.13 +  0.13 1 -45 ± 0.13 3.04 ± 0.66* 3.31 ±0.56*
Metadrenaline (pmol/ml) 0.24 +  0.02 0.23 +  0.02 0.30 ± 0.06 0.25 ± 0.02
Metadrenaline sulphate (pmol/ml) 3.53 +  0.37 3.62 +  0.36 5.12 ± 1.24 9.12 ± 2.17*
Adrenaline (pmol/ml) 0.31+0.08 0.28 ± 0.04 0.41 ±0.1 i 0.54 ± 0.08*
DHPG (pmol/ml) 4.85 +  0.22 5.68+0.38 4.74 ± 0.32 6.80 ±0.32*
Norrie disease. The five patients with Norrie 
disease showed considerable increases ( P c  0.001) 
above normal in forearm venous plasma concent­
rations of free (6.1-fold increase) and conjugated 
(15.7-fold increase) normetadrenaline (Table 2). 
Plasma concentrations of free and conjugated 
metadrenaline were also increased (PcO.Ol), 
although the extent of these increases was not as 
large (about a third) as those observed for free and 
conjugated normetadrenaline. Plasma concent­
rations of conjugated metadrenaline and normet­
adrenaline were increased 50 and 160% above 
normal than the respective concentrations of free 
metadrenalines. Plasma noradrenaline was increased 
by 2-fold ( P c 0.05) in Norrie disease patients, where­
as plasma adrenaline was unaffected. Plasma 
concentrations of DHPG were below the limits of 
detection ( P c 0.02) in all five patients with Norrie 
disease.
Angina pectoris. Patients with angina pectoris had 
higher ( P c 0.05) arterial plasma concentrations of 
conjugated normetadrenaline than control subjects, 
but apart from this there were no other differences 
for this subject group (Table 3).
Renal artery stenosis. Plasma concentrations of 
noradrenaline and free and conjugated normet­
adrenaline were 2.1- to 2.7-fold higher (PcO.Ol) in 
patients with renal artery stenosis than in control 
subjects, whereas concentrations of adrenaline and 
free and conjugated metadrenaline were not differ­
ent (Table 3).
Cardiac failure. Cardiac failure was associated 
with 2.3- to 3.6-fold higher ( P c 0.001) plasma con­
centrations of noradrenaline and free and conju­
gated normetadrenaline than in control subjects 
(Table 3). Plasma concentrations of adrenaline and
metadrenaline sulphate were also increased
(PcO  .01) in patients with heart failure, but concent­
rations of free metadrenaline were not affected.
Relationships among plasma catecholamines and 
metabol ites
There were significant ( P c 0.001) positive rela-
renaline and normetadrenaline or DHPG, as well as 
between plasma concentrations of adrenaline and 
metadrenaline (Fig. 1). Although all linear regres­
sion lines intersected the y-axis (metabolite axis) 
above the origin, this was most apparent for the 
regression line describing the relationship between 
plasma noradrenaline and DHPG.
Positive linear relationships ( P c 0.001) were also 
observed between plasma concentrations of free and 
sulphate-conjugated normetadrenaline or metadren­
aline (data not shown).
Infusion of 3H-labelled catecholamines
[3H]noradrenaline were reached within 20 min of
Steady-state plasma concentrations of
the
3
start of the intravenous infusion of
[ H]noradrenaline (Fig. 2). Plasma concentrations 
of free [ 3H]normetadrenaline increased during the
first 30 min of the [3H]noradrenaline infusion, 
reaching steady-state concentrations by 60 min after 
the start of the infusion that were 3.1 ±0.2% of 
those of [3H]noradrenaline concentrations. In con­
trast, plasma concentrations of [3H]DHPG conti­
nued to climb throughout the infusion so that, at 
90 min after the start of infusion, concentrations of 
[3H]DHPG were higher than those of
[3H]normetadrenaline. Between 60 and 90 min after 
the start of the [3H]noradrenaline infusion, the
specific activity of free [ H]normetadrenaline was 
89±5d.p.m./pmol, significantly lower than the spe­
cific activity of [3H]noradrenaline (527 ±  53 d.p.m./ 
pmol), but significantly higher than that of 
[3H]DHPG (7.4± 0.5 d.p.m./pmol).
During simultaneous infusion of 3H-labelled nor­
adrenaline and adrenaline, plasma concentrations of 
free [3H]metadrenaline increased to 6.2 ±0.5% of 
steady-state plasma [3H]adrenaline concentrations,
about 2-fold higher than the increase in
[3H]normetadrenaline relative to [3H]noradrenaline 
concentrations (Fig. 3a).
Comparison of the ratio of steady-state arterial 
plasma concentrations of free [3H]normetadrenaline 
to [3H]noradrenaline with the ratio of arterial
tionships between plasma concentrations of norad- plasma concentrations of endogenous normetadre-
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naline to noradrenaline, indicated that 15.8 + 1.4% 
of the endogenous free normetadrenaline in plasma 
was derived from metabolism of noradrenaline after 
it entered the circulation (Fig. 3b). Surprisingly, 
ratios of 3H-labelled and endogenous metadrenaline 
to adrenaline indicated that only 10.1 ±1.9% of the 
endogenous free metadrenaline in plasma was der­
ived from adrenaline after it was released into the 
circulation, a proportion that was actually less
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ived from samples taken at different times after the start of infusions and 
partitioned into 15 min collection periods.
(PcO.Ol) than that for the endogenous normetadren­
aline produced from circulating noradrenaline.
Inferior vena cava blood sampling
In the patient who underwent inferior vena cava 
regional blood sampling, the plasma concentration 
of adrenaline in the right adrenal vein was 45-fold 
higher than in the downstream vena cava sampling 
site (Table 4). The plasma concentration of met­
adrenaline was 12-fold higher in the adrenal vein
i
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Fig. 3. Plasma concentrations of 3H-labelled normetadrenaline or 
metadrenaline as a percentage of steady-state plasma concent­
rations of intravenously infused [3H]noradrenaline or [^adrena­
line (a). These ratios were used in conjunction with ratios of endogenous 
normetadrenaline to noradrenaline, or metadrenaline to adrenaline, to 
estimate (see Data analysis in the Methods section) the percentage amounts 
of endogenous normetadrenaline or metadrenaline in plasma that were 
derived from metabolism of noradrenaline or adrenaline after release of 
precursor amines into the circulation (b). Results represent means with 
SEMs represented by vertical bars. *Denotes a significant difference 
between metadrenaline and normetadrenaline as determined by Wilcoxon’s 
signed rank sum test.
%
than in the vena cava. The plasma normetadrenaline 
concentration was also higher in the adrenal vein 
than at other sampling sites. Plasma concentrations 
of adrenaline and metadrenaline were higher in the 
left renal vein, which drains both the left kidney and 
adrenal gland, than in the right renal vein, which 
drains only the right kidney.
Activation of sympathetic outflow
Application of —40 mmHg of lower body negative 
pressure, mental challenge and supine cycling exer­
cise all increased (PcO.Ol) plasma normetadrenaline 
and plasma noradrenaline. Percentage increases in 
plasma normetadrenaline were considerably and 
consistently lower (PcO.Ol) than increases in 
plasma noradrenaline in response to all stimuli (Fig. 
4a).
Lower body negative pressure, mental challenge 
and cycling exercise also increased ( P c 0.001) 
plasma adrenaline, but only lower body negative 
pressure increased plasma metadrenaline. Again, 
metadrenaline responses were considerably and con­
sistently smaller than adrenaline responses to all 
stimuli (Fig. 4b).
DISCUSSION «
The results show that measurement of plasma 
metadrenalines provides information about 
sympatho-adrenal activity that supplements that 
provided by the parent amines. More importantly, 
these metabolites provide information about cate­
cholamine metabolism in extraneuronal tissues, 
including the adrenal medullae, that is not available 
from measurements of the parent amines alone.
Other reports about the clinical utility of plasma 
metadrenalines for assessment of sympatho-adrenal 
activity are largely limited to those of DeQuattro 
and colleagues [9, 10, 20-23], who used a radioen- 
zymic assay to measure plasma concentrations of 
normetadrenaline in hypertension and during vari­
ous manipulations of sympathetic outflow. The 
radioenzymic assay depends on N-terminal méthyla­
tion of normetadrenaline, so that metadrenaline 
cannot be measured. The present use of liquid 
chromatography with electrochemical detection 
allows measurements of both metadrenaline and 
normetadrenaline.
The much lower plasma concentrations of free 
normetadrenaline than of noradrenaline, but higher 
concentrations of normetadrenaline sulphate, the 
age-dependence of plasma noradrenaline and nor­
metadrenaline, higher plasma concentrations in 
hypertensive than in normotensive subjects and 
increases in concentrations during sympathetic acti­
vation agree well with previous findings [9, 10, 20- 
25]. The parallel increases in plasma normetadrena­
line and noradrenaline in heart failure also support 
the view that plasma normetadrenaline reflects sym­
pathetic outflow. Thus, measurement of normetadren­
aline as an index of sympathetic outflow provides 
supplementary information that may strengthen the 
conclusions derived from measurements of noradren­
aline. However, the proportionally smaller changes 
in plasma concentrations of free normetadrenaline 
than of noradrenaline during mental challenge, 
lower body negative pressure and exercise, indicate 
that normetadrenaline is a less sensitive index of 
acute changes in sympathetic outflow than 
noradrenaline.
Similarly, the much smaller increases in plasma 
metadrenaline than adrenaline during sympatho­
adrenal activation also indicate that changes in 
plasma metadrenaline are a less sensitive index of 
acute changes in adrenal medullary secretion of 
adrenaline than the parent amine itself. Neverthe­
less, the findings of higher plasma concentrations of 
adrenaline in hypertensive than in normotensive 
subjects and in males than in females, while consis­
tent with other studies [26, 27], are further sup­
ported and strengthened by similar differences in
plasma concentrations of free or sulphate-
conjugated metadrenaline.
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Table 4. Plasma concentrations of catecholamines and metadrenalines during regional sampling of renal and adrenal 
veins in a single patient
Plasma concn. (pmol/ml)
Adrenaline Metadrenaline Noradrenaline Normetadrenaline
Vena cava (inferior lower)* 0.34 0.20 1.91 0.43
Right renal vein 0.52 0.14 4.37 0.38
Left renal vein 2.01 0.27 4.81 0.43
Right adrenal vein 15.30 2.45 3.46 0.67
Vena cava (inferior upper)* 0.49 0.20 2.50 0.49
*The inferior vena cava was sampled at two places, downstream (inferior lower) and upstream (inferior upper) from renal and adrenal venous 
sampling sites.
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Fig. 4. Percentage increases in plasma concentrations of normetad­
renaline compared with noradrenaline (a) and of metadrenaline 
compared with adrenaline (b) in response to mental challenge (i.e. 
playing a video game), application of -40 mmHg lower body 
negative pressure (LBNP) and supine cycling exercise. Values are 
expressed as means with SEMs represented by vertical bars. ^Denotes a 
significant difference between normetadrenaline and noradrenaline res­
ponses, or metadrenaline and adrenaline responses, as determined by 
Wilcoxon's signed rank sum test.
An explanation for the insensitivity of plasma 
metadrenalines to acute changes in sympatho­
adrenal activation is provided by the observations 
about production of free metadrenalines from 
infused catecholamines. Similar plasma concent­
rations of endogenous metadrenaline to adrenaline, 
despite increases in plasma metadrenaline that were 
only 6% of those of infused adrenaline, indicated 
that most (90%) of the free metadrenaline in plasma
is derived from metabolism of adrenaline before its 
release into the circulation, and is therefore unlikely 
to be responsive to acute changes in adrenaline 
release. The relative independence of metadrenaline 
production on adrenaline release is further reflected 
by the regression line for the relationship between 
plasma metadrenaline and adrenaline that inter­
sected the y-axis well above the origin. Comparison 
of the ^-intercept value of metadrenaline (0.13 pmol/ 
ml) with mean plasma concentrations of metadrena­
line in control subjects (0.14 pmol/ml) indicates that 
90% of metadrenaline in plasma is independent of 
adrenaline release into the circulation.
Other findings in adrenalectomized rats showing 
normal plasma concentrations of metadrenaline 
despite undetectable adrenaline concentrations, sug­
gested that much of the metadrenaline in plasma 
might be derived from adrenaline synthesized at 
extra-adrenal sites [6]. The results in patients with 
bilateral adrenalectomy indicate that, in humans, at 
least 91% of the metadrenaline in plasma is derived 
from adrenaline synthesized in the adrenals. This 
could reflect metabolism of adrenaline within the 
adrenals or local metabolism of adrenaline taken up 
and released by extra-adrenal tissues after synthesis 
and initial release by the adrenals. The former 
source is suggested by the high metadrenaline con­
centrations in plasma draining the adrenal veins.
Higher plasma concentrations of normetadrena­
line in the adrenal vein than the vena cava, the 
lower ratio of normetadrenaline to noradrenaline 
concentrations in adrenalectomized patients than 
control subjects, and other findings of higher left 
renal than right renal venous plasma normetadrena­
line concentrations [9], indicate that some circulat­
ing normetadrenaline is also derived from metabo­
lism of noradrenaline within the adrenals. A 
contribution of the adrenals to plasma normetadren­
aline is consistent with the regression line for the 
relationship between plasma noradrenaline and nor­
metadrenaline that intersected the y-axis above the 
origin. Comparison of the ^-intercept value of nor­
metadrenaline (0.11 pmol/ml) with mean plasma 
concentrations of normetadrenaline in control sub­
jects (0.29 pmol/ml), suggests a 38% contribution of 
the adrenals to plasma normetadrenaline. Similarly, 
comparison of the ratio of plasma normetadrenaline 
to noradrenaline in adrenalectomized (0.144) and
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control (0.254) subjects, indicates a 45% 
[(0.254 — 0.144)/0.244] contribution of the adrenals 
to plasma concentrations of normetadrenaline. For­
mation of metadrenalines within the adrenals is 
further supported by immunohistochemical findings 
of COMT-positive cells in cortical layers of the 
adrenal gland [28, 29].
Although the metadrenalines provide little new 
information about sympatho-adrenal activity to that 
provided by the parent amines, the source of these 
metabolites makes them particularly useful for 
examination of catecholamine metabolism in extra­
neuronal tissues, including the adrenal medullae and 
tumours of chromaffin-cell origin. Comparison of 
plasma concentrations of catecholamines and 
metadrenalines in a large group of phaeochromocy­
toma patients showed that plasma metadrenalines 
were increased more consistently, and considerably 
more above normal, than plasma catecholamines (J. 
Lenders et al., unpublished work). In particular, 
patients with Von Hippel-Lindau’s disease, a geneti­
cally inherited disorder associated with susceptibility 
to develop phaeochromocytomas, show increased 
plasma metadrenalines well before other tests (e.g. 
plasma catecholamines, clonidine suppression, gluca­
gon stimulation) provide a positive diagnosis of the 
tumour. The extraordinarily high sensitivity of 
plasma metadrenalines for diagnosis of phaeochro­
mocytoma can be explained by the present findings 
of active O-methylation of catecholamines within 
the adrenal gland, and presumably therefore in 
tumours derived from chromaffin tissue. High con­
centrations of normetadrenaline in the venous N 
drainage of phaeochromocytomas [22] support this 
possibility. Even when quiescent or not releasing 
catecholamines, the tumours appear to be actively 
metabolizing catecholamines to the O-methylated 
derivatives.
Although as much as 40% of plasma normetadren­
aline is derived from metabolism of noradrenaline 
within the adrenal medullae, most (60%) is derived 
from extraneuronal metabolism of neuronally 
released noradrenaline before or after entry of the 
transmitter into the circulation. The increases in 
plasma concentrations of free normetadrenaline 
from infused noradrenaline indicate that 16% of the 
free normetadrenaline in plasma is derived from 
metabolism of circulating noradrenaline. Thus, 73% 
[(60—16)/60] of the normetadrenaline that is der­
ived from neuronally released noradrenaline is 
formed by extraneuronal metabolism before entry of 
the transmitter into the circulation, leaving 27% 
formed from metabolism after entry of noradrena­
line into the circulation. This compares with the 
neuronal metabolite of noradrenaline, DHPG, of 
which less than 2% is derived from circulating 
noradrenaline [7].
The extraneuronal source of normetadrenaline, as 
distinct from the neuronal source of DHPG, is 
reflected by the relationships of normetadrenaline 
and DHPG with noradrenaline and production of
both metabolites from infused [3H]noradrenaline. 
The regression line for the relationship between 
plasma noradrenaline and DHPG intersected the y- 
axis well above the origin, consistent with formation 
of most DHPG from metabolism of noradrenaline 
leaking from vesicles and not released by nerves [3,
4, 30]. In contrast, the relationship between nor­
metadrenaline and noradrenaline intersected the y- 
axis closer to the origin, consistent with formation 
of most (60%) normetadrenaline from neuronally 
released noradrenaline.
During infusion of [3H]noradrenaline, the pro­
gressive increase in plasma [3H]DHPG with time 
reflects continuous loading of neuronal vesicular 
stores with [3H]noradrenaline and the substantial 
contribution by leakage of noradrenaline from these 
stores to DHPG production [18]. In contrast, 
attainment of steady-state plasma concentrations of 
[3H]normetadrenaline indicates production of this 
metabolite from extraneuronal sites, where loading 
of vesicular stores exerts no influence. Similarly, the 
much lower specific activities of [3H]DHPG com­
pared with [3H]normetadrenaline reflect the differ­
ent sources of these metabolites from neuronal and 
extraneuronal sites and the much larger contribu­
tion of circulating noradrenaline to production of 
normetadrenaline than DHPG.
The potential use of plasma metadrenalines for 
the clinical examination of extraneuronal catechola­
mine metabolism is clearly demonstrated in the 
patients with Norrie disease, where the deficiency of 
MAO was reflected not only by the complete 
absence of intraneuronal DHPG production, but 
also by considerably increased plasma concent­
rations of metadrenalines. Plasma normetadrenaline 
was increased about 3-fold more than metadrena­
line, consistent with findings in rats where pharma­
cological blockade of MAO increased plasma nor­
metadrenaline 3-fold more than metadrenaline, a 
difference due to both increased formation and 
decreased plasma clearance of normetadrenaline and 
only decreased clearance of metadrenaline [8]. 
These findings indicated that little adrenaline or 
metadrenaline is deaminated in the compartment 
where metadrenaline is formed, a result explained 
by differences in rate constants for deamination of 
adrenaline and noradrenaline. The present findings, 
showing that most metadrenaline is formed within 
the adrenals, offer a more likely explanation for the 
observation that little adrenaline or metadrenaline is 
deaminated in the compartment where metadrena­
line is formed [8].
The marked changes in metabolite profiles in 
Norrie disease patients illustrate how measurements 
of plasma metadrenalines in relation to other meta­
bolites, such as DHPG, may be particularly useful 
for identification of disorders affecting catechola­
mine metabolism. Specifically, the pattern of 
increased plasma concentrations of metadrenalines 
and decreased concentrations of deaminated meta­
bolites is characteristic of MAO-deficiency states.
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The use of a ratio of these two metabolite groups, 
while not necessary for identification of the com­
plete absence of MAO gene expression in the Norrie 
disease patients studied here, might provide the 
most sensitive index for detection of partial MAO- 
deficiency states. Recent identification of a point 
mutation of the MAO-A gene, associated with 
bizarre disturbances of behaviour [31, 32], raises the 
possibility that other as yet unrecognized deficits in 
MAO function may exist, associated with more 
subtle neuropsychological manifestations. Also, 
recent mapping of the COMT gene to the same site 
on chromosome 22 [33] where deletions are respon­
sible for DiGeorge’s syndrome [34], suggests that 
defective expression of the COMT gene may contri­
bute to the psychosis associated with this syndrome 
[35]. Measurements of plasma metadrenalines in 
conjunction with deaminated metabolites, provide a 
straightforward approach to detect and quantify 
neurochemical phenotypes in genetic disorders of 
catecholamine metabolism and turnover.
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